Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders

A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders

The purpose of the study is to determine if SJP-0035 ophthalmic solution is effective in promoting corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

Study Overview

• Status: Completed
• Conditions: Corneal Epithelial Disorders
• Intervention / Treatment: Drug: SJP-0035 Ophthalmic Solution; Drug: Vehicle of SJP-0035 Ophthalmic Solution

Detailed Description

There is currently no product approved for corneal epithelial wound healing. A Phase 1 Study SJP-0035/1-01 was conducted in healthy volunteers to investigate the safety, tolerability, and pharmacokinetic profile of SJP-0035 ophthalmic solution and to determine the appropriate dose to be evaluated in patients with moderate to severe corneal epithelial disorders.

This Phase 2a study is being conducted to evaluate the safety and efficacy of SJP-0035 ophthalmic solution in patients to promote corneal epithelial wound healing in conditions associated with corneal epithelial disorders.

• Study Type: Interventional
• Enrollment (Actual): 69
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Senju Investigational Site
  • California
    • Glendale, California, United States, 91206
      • Senju Investigational Site
    • Glendora, California, United States, 91741
      • Senju Investigational Site
    • Huntington Beach, California, United States, 92647
      • Senju Investigational Site
    • Lancaster, California, United States, 93534
      • Senju Investigational Site
    • Newport Beach, California, United States, 92663
      • Senju Investigational Site
    • Pasadena, California, United States, 91107
      • Senju Investigational Site
    • Petaluma, California, United States, 94954
      • Senju Investigational Site
    • Santa Maria, California, United States, 93454
      • Senju Investigational Site
  • Illinois
    • Hoffman Estates, Illinois, United States, 60169
      • Senju Investigational Site
  • Kentucky
    • Edgewood, Kentucky, United States, 41017
      • Senju Investigational Site
  • Missouri
    • Kansas City, Missouri, United States, 64111
      • Senju Investigational Site
  • New Jersey
    • Palisades Park, New Jersey, United States, 07650
      • Senju Investigational Site
  • New York
    • Rochester, New York, United States, 14642
      • Senju Investiational Site
  • North Carolina
    • High Point, North Carolina, United States, 27262
      • Senju Investigational Site
  • South Dakota
    • Rapid City, South Dakota, United States, 57701
      • Senju Investigational Site
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Senju Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female between the ages of 18 and 75 years, inclusive.
• Has moderate to severe superficial punctate keratitis (SPK) and/or corneal erosion in 1 or both eyes.
• Has symptoms caused by corneal epithelial disorders.
• Has not obtained improvement from previous treatment for the SPK or corneal erosion within the last 30 days.
• Is a female of childbearing potential with a negative pregnancy test result at Screening and baseline and agrees to use effective contraception throughout the study or is a postmenopausal woman with a negative pregnancy test result at Screening and baseline.

Exclusion Criteria:

• Has any corneal stromal or endothelial abnormalities including an active bacterial or viral ocular infection, bullous keratopathy, or chemical burns or any trauma to the cornea.
• Any active or chronic allergic, bacterial, or viral infection of ocular adnexa and eye structures.
• Had previous ocular/refractive surgery (including laser surgery) within the last 6 months.
• Has used any ocular medication (except mydriatics, stain, and topical anesthesia used for study assessments) within 14 days prior to the first dose of study drug, or who are anticipated to require such medications during the study. Artificial tears may be used up to 72 hours prior to the first dose.
• Is unable to discontinue Restasis. A 28-day washout period prior to the first dose of study drug is required.
• Is a contact lens wearer and cannot discontinue use for the duration of the study.
• Alcohol or drug abuse within the past 6 months.
• Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus test at Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SJP-0035 Ophthalmic Solution; Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.	Drug: SJP-0035 Ophthalmic Solution
Placebo Comparator: Vehicle of SJP-0035 Ophthalmic Solution; Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.	Drug: Vehicle of SJP-0035 Ophthalmic Solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clearing of corneal fluorescein staining at week 4	A patient will be considered a success for clearing of corneal fluorescein staining if their fluorescein staining has disappeared.	measured at Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Adverse Events as a Measure of Safety.	An Adverse Event is defined as any untoward medical occurrence in a patient enrolled into the study regardless of its causal relationship to study drug.	baseline up to week 18
Changes of subjective symptoms: blurred vision, photophobia and eye irritation	100-point assessments are performed for the symptom of blurred vision, photophobia and eye irritation.	screening up to week 18
Changes of subjective signs: tear stability, conjunctival epithelia, and surface curvature of cornea	These changes are measured at every study visit using standard ophthalmology procedures.	screening up to week 18

Collaborators and Investigators

• Sponsor: Senju Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 8, 2014
• Primary Completion (Actual): August 4, 2015
• Study Completion (Actual): August 4, 2015

Study Registration Dates

• First Submitted: March 19, 2014
• First Submitted That Met QC Criteria: April 3, 2014
• First Posted (Estimate): April 4, 2014

Study Record Updates

• Last Update Posted (Actual): March 29, 2021
• Last Update Submitted That Met QC Criteria: March 25, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Ophthalmic Solutions; Pharmaceutical Solutions
• Other Study ID Numbers: SJP-0035/2-01